Cytokinetics Up 9% (CYTK)
Cytokinetics, Inc. (NASDAQ: CYTK) shares are significantly higher this morning, gaining 9% to $1.69, a gain of 14 cents on 27,000 shares so far this morning.
Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.